



Unmet needs in Multiple Myeloma



Multiple myeloma (MM) is the **second most common blood cancer**.¹



An estimated **30,770 new cases** of MM were diagnosed **in the U.S. in 2018**.²


40,000 people were diagnosed with MM **in Europe in 2015**, and this number is predicted to **increase to almost 46,000 by 2025**.³

124,733


124,733 people were estimated to be **living with myeloma in the U.S.**, in 2015.²



While myeloma can affect adults of any age, it is much **more common in people aged over 65 years**, and in **men rather than women**.³



Almost all patients with MM will eventually relapse.⁴ The patient **survival rate for MM up to five years is 50.7% in the U.S.**,² and around **40% in England**.⁵



Between **15-19% will live for at least 10 years**.⁵

1. International Myeloma Foundation. March is Myeloma Action Month. <http://mam.myeloma.org/> Last accessed 20 March 2019. 2. NIH National Cancer Institute. Cancer Stats Facts Myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html> Last accessed 20 March 2019. 3. Myeloma Patients Europe. Incidence of myeloma. <https://www.mpeurope.org/about-myeloma/incidence-of-myeloma/> Last accessed 20 March 2019. 4. Myeloma Patients Europe. Treatment of Myeloma <https://www.mpeurope.org/about-myeloma/treatment-of-myeloma/> Last accessed 20 March 2019. 5. Myeloma Patients Europe. Prognosis. <https://www.mpeurope.org/about-myeloma/prognosis/> Last accessed 20 March 2019.

